Declaration of competing financial interests
From the following article:
Epigenetic therapy of cancer: past, present and future
Christine B. Yoo & Peter A. Jones
Nature Reviews Drug Discovery 5, 37-50 (January 2006)
doi:10.1038/nrd1930
Declaration: P.A.J. is a consultant to and shareholder of Epigenomics AG and is on the Speakers Bureau for MGI Pharma which is developing decitabine. C.B.Y. does not have any competing financial interest.
